This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

The content of this website has been produced in line with the BOSULIF®▼ (bosutinib) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BOSULIF Prescribing Information for Great Britain and for Northern Ireland, and adverse event reporting information can be found at the bottom of the page.

Bosulif®(bosutinib)

Bosulif

Bosulif has been authorised under a conditional approval scheme. Since Bosulif has been granted a conditional approval, the company that markets Bosulif will carry out and submit the results of a larger study with Bosulif in patients with Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitors (TKIs) and for whom dasatinib, imatinib and nilotinib are not considered appropriate treatment options.1

BOSULIF is indicated for the treatment of adult patients with2:

  • Newly-diagnosed chronic phase (CP) Ph+ CML
  • CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options​​​​​​​

TKIs in CML

Watch Prof. Richard Clark discuss the holistic approach to treatment decisions for patient with CML

Learn more on TKIs in CML

Efficacy

Understand the data for Bosulif in 2nd line and beyond

View Study 200 data

New challenges: long-term TKI therapy

Hear Dr. Alex Lyon’s views on long-term TKI treatment in an ageing patient population video

Learn more on new challenges in CML

If you wish to discuss BOSULIF with one of our representatives, please click here to fill in a form so we may contact you at a convenient time

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
References:
  1. European Medicines Agency. EPAR, bosutinib (EMEA/H/C/002373). Available at: https://www.ema.europa.eu/en/documents/overview/bosulif-epar-medicine-overview_en.pdf [accessed September 2021]
  2. BOSULIF Summary of Product Characteristics for Great Britain click here.  BOSULIF Summary of Product Characteristics for Northern Ireland click here.
PP-BOS-GBR-1292. September 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No